The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative

by M. Yldau van der Ende, Ingmar E. Waardenburg, E. Lipsic, Jens H.J. Bos, Eelko Hak, H. Snieder, Pim van der Harst
Published 2020-09-01

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

by A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides
Published 2021-06-01